Skip to main content

RT @uptoTate: Preliminary results anifrolumab may be effective in highly recalcitrant & RTX resistant CLE and DLE. A

Social Author Name
Dr. Rachel Tate
Tweet Content
Preliminary results anifrolumab may be effective in highly recalcitrant & RTX resistant CLE and DLE. Abs 0974 #ACR22 @RheumNow https://t.co/FeYrdlwQsA
Show on Archive Page
On
Display in Search Results
On
PDQ
Off